IL240196B - Amide compounds, preparations containing them and their uses - Google Patents

Amide compounds, preparations containing them and their uses

Info

Publication number
IL240196B
IL240196B IL240196A IL24019615A IL240196B IL 240196 B IL240196 B IL 240196B IL 240196 A IL240196 A IL 240196A IL 24019615 A IL24019615 A IL 24019615A IL 240196 B IL240196 B IL 240196B
Authority
IL
Israel
Prior art keywords
compositions
same
amide compounds
amide
compounds
Prior art date
Application number
IL240196A
Other languages
English (en)
Hebrew (he)
Other versions
IL240196A0 (en
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL240196A0 publication Critical patent/IL240196A0/en
Publication of IL240196B publication Critical patent/IL240196B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
IL240196A 2013-01-31 2015-07-28 Amide compounds, preparations containing them and their uses IL240196B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759062P 2013-01-31 2013-01-31
PCT/US2014/013667 WO2014120820A1 (en) 2013-01-31 2014-01-29 Amides as modulators of sodium channels

Publications (2)

Publication Number Publication Date
IL240196A0 IL240196A0 (en) 2015-09-24
IL240196B true IL240196B (en) 2019-08-29

Family

ID=50114569

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240196A IL240196B (en) 2013-01-31 2015-07-28 Amide compounds, preparations containing them and their uses

Country Status (15)

Country Link
US (2) US9108903B2 (show.php)
EP (1) EP2951155B1 (show.php)
JP (1) JP6346622B2 (show.php)
KR (1) KR102226588B1 (show.php)
CN (1) CN104968647B (show.php)
AR (1) AR094668A1 (show.php)
AU (1) AU2014212431B2 (show.php)
BR (1) BR112015018284B1 (show.php)
CA (1) CA2898653C (show.php)
IL (1) IL240196B (show.php)
MX (1) MX359882B (show.php)
RU (1) RU2658920C2 (show.php)
SG (1) SG11201505954RA (show.php)
TW (1) TWI659945B (show.php)
WO (1) WO2014120820A1 (show.php)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
GEP20207082B (en) 2013-12-13 2020-04-10 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
JP7104070B2 (ja) 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
EP3651752B1 (en) 2017-07-11 2024-11-20 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 疼痛を処置する方法
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
AU2020205139A1 (en) * 2019-01-04 2021-08-19 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
KR20210131357A (ko) * 2019-02-20 2021-11-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 6-옥소-1,6-디하이드로피리다진 프로드러그 유도체, 이의 제조 방법, 및 의약에서의 이의 응용
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CA3150400A1 (en) * 2019-09-12 2021-03-18 Shanghai Jemincare Pharmaceuticals Co., Ltd Pyridine oxynitride, preparation method therefor and use thereof
UA130303C2 (uk) 2019-12-06 2026-01-14 Вертекс Фармасьютикалз Інкорпорейтед Заміщені тетрагідрофурани як модулятори натрієвих каналів
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
TWI806073B (zh) 2020-06-17 2023-06-21 美商默沙東有限責任公司 作為nav1.8抑制劑之2-氧基咪唑啶-4-甲醯胺
AU2021292061A1 (en) 2020-06-17 2023-01-19 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as Nav1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN114031518B (zh) * 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
CN112225695B (zh) * 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
US20240208908A1 (en) * 2021-03-11 2024-06-27 Shanghai Jemincare Pharmaceutical Co., Ltd Crystal form of pyridine nitrogen oxide compound and use thereof
PE20250021A1 (es) 2021-05-07 2025-01-07 Merck Sharp And Dohme Llc Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
EP4346818B1 (en) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
JP2024522293A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US20250388541A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
PE20251179A1 (es) 2022-04-22 2025-04-23 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
TW202434235A (zh) * 2023-01-18 2024-09-01 芬蘭商奧利安公司 3-(4,5-二氯-2-(4-(三氟甲氧基)苯氧基)苯甲醯胺基)吡啶1-氧化物的製備方法
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2511231A (en) 1949-03-26 1950-06-13 Eastman Kodak Co 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
AU2007238857B2 (en) 2006-04-11 2013-05-02 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
AU2008310663A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
NZ584474A (en) * 2007-10-11 2012-06-29 Vertex Pharma Amides useful as inhibitors of voltage-gated sodium channels
EP3632899A1 (en) * 2009-05-29 2020-04-08 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Also Published As

Publication number Publication date
CA2898653A1 (en) 2014-08-07
US9108903B2 (en) 2015-08-18
HK1217692A1 (en) 2017-01-20
CA2898653C (en) 2021-09-28
US9421196B2 (en) 2016-08-23
JP6346622B2 (ja) 2018-06-20
KR20150118964A (ko) 2015-10-23
RU2658920C2 (ru) 2018-06-26
CN104968647A (zh) 2015-10-07
CN104968647B (zh) 2018-01-26
US20150328196A1 (en) 2015-11-19
AU2014212431A1 (en) 2015-08-06
AU2014212431B2 (en) 2018-04-05
US20140221435A1 (en) 2014-08-07
NZ710293A (en) 2020-09-25
BR112015018284B1 (pt) 2023-03-07
WO2014120820A9 (en) 2015-07-02
EP2951155A1 (en) 2015-12-09
TW201443005A (zh) 2014-11-16
WO2014120820A1 (en) 2014-08-07
AR094668A1 (es) 2015-08-19
KR102226588B1 (ko) 2021-03-11
MX2015009591A (es) 2016-04-15
BR112015018284A2 (pt) 2017-07-18
JP2016508500A (ja) 2016-03-22
SG11201505954RA (en) 2015-08-28
MX359882B (es) 2018-10-15
RU2015136779A (ru) 2017-03-07
TWI659945B (zh) 2019-05-21
EP2951155B1 (en) 2019-06-19
IL240196A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
IL269964B2 (en) Pyridone amide compounds, compositions containing them and uses thereof
IL240196B (en) Amide compounds, preparations containing them and their uses
IL274355B (en) Aza-pyridone compounds and their uses
IL246061B (en) Prodrugs of pyridone amide, preparations containing them and their uses
IL240091B (en) Quinoline and quinoxaline amides, preparations containing them and their uses
IL244850B (en) Stabilized epinaconazole preparations, and their uses
IL243752A0 (en) Multispecific antibodies, preparations containing them and their uses
IL241330A0 (en) pk - dna suppressor compounds, preparations containing them and their uses
IL241355A0 (en) Pyrazole-amide compounds, preparations containing them and their uses
IL241352A0 (en) Compounds of pyruvate kinase plants, preparations containing them and their uses
IL241225A0 (en) Plant-based compositions and their uses
IL238958A0 (en) Glutamase inhibitors, preparations containing them and their uses
IL234014A0 (en) Cycloalkane derivatives, preparations containing them and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
IL243495B (en) Compressed piperidine amides, preparations containing them and their uses
GB201323008D0 (en) Compounds and uses thereof
GB201321693D0 (en) Composition and uses thereof
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL241358A0 (en) Compounds derived from mannose, preparations containing them and their uses
IL241359A0 (en) Converted indole-5-ol derivatives, preparations containing them and their uses
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201307233D0 (en) Compounds and uses thereof
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
SG11201600266VA (en) Uv absorbing compounds, compositions comprising same and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed